Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: ICAD

Market Cap 11Cr 9.16Cr 8.45Cr 7.91Cr 15Cr 1.01TCr 15Cr 100.76Cr 39Cr 487.36Cr 40Cr 39Cr 1.69TCr P/E Ratio 2023
-9.35x
P/E Ratio 2024 -8.59x
Enterprise Value 8.87Cr 7.7Cr 7.1Cr 6.65Cr 12Cr 849.78Cr 13Cr 85Cr 33Cr 409.62Cr 33Cr 33Cr 1.42TCr EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
1 year 3.58
Extreme 3.58
3.99
3 years 1.14
Extreme 1.14
4.02
5 years 1.05
Extreme 1.05
19
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 10/03/2023
Director of Finance/CFO 54 17/07/2025
Corporate Secretary - 17/07/2025
Date Insider Type Main position Quantity % Market Cap.
17/25/17Issuer sale

Director

15,53,657 5.8540%
17/25/17Issuer sale

Director

3,32,572 1.2531%
17/25/17Issuer sale

Director

2,46,115 0.9273%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--%+0.52%+222.50% 11Cr
-1.32%-1.32%+14.58%-8.21% 18TCr
+0.21%-1.41%-20.96%+32.02% 15TCr
-1.55%-3.13%-11.69%-23.19% 13TCr
-2.42%-3.44%-52.55%-8.01% 7.01TCr
-0.26%-1.93%+13.63%+1.97% 4.94TCr
+1.21%+0.14%-24.82%-33.82% 4.42TCr
-1.57%-6.37%+8.21%+11.88% 3.66TCr
-0.95%-4.44%+3.96%+44.31% 3.53TCr
+1.18%+1.10%-12.11%-16.33% 2.93TCr
Average +0.04%-1.95%-8.12%+22.31% 7.16TCr
Weighted average by Cap. -0.49%-2.08%-8.39%-0.21%

Financials

2023 2024
Net sales 1.73Cr 1.5Cr 1.39Cr 1.3Cr 2.43Cr 165.82Cr 2.48Cr 17Cr 6.4Cr 80Cr 6.5Cr 6.36Cr 277.92Cr 1.96Cr 1.7Cr 1.57Cr 1.47Cr 2.75Cr 187.75Cr 2.8Cr 19Cr 7.24Cr 91Cr 7.36Cr 7.2Cr 314.67Cr
Net income -48.47L -42.06L -38.77L -36.33L -67.88L -46Cr -69.29L -4.63Cr -1.79Cr -22Cr -1.82Cr -1.78Cr -78Cr -56.16L -48.74L -44.92L -42.09L -78.65L -54Cr -80.29L -5.36Cr -2.07Cr -26Cr -2.11Cr -2.06Cr -90Cr
Net Debt -2.12Cr -1.84Cr -1.7Cr -1.59Cr -2.97Cr -203.08Cr -3.03Cr -20Cr -7.84Cr -98Cr -7.96Cr -7.79Cr -340.37Cr -1.68Cr -1.46Cr -1.35Cr -1.26Cr -2.36Cr -161.28Cr -2.41Cr -16Cr -6.22Cr -78Cr -6.32Cr -6.19Cr -270.32Cr
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!